Literature DB >> 7904231

The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines.

J Liebmann1, J A Cook, C Lipschultz, D Teague, J Fisher, J B Mitchell.   

Abstract

We have performed DNA flow analysis, mitotic index studies, time-lapse photography, and paclitaxel uptake studies of human tumor cell lines exposed to paclitaxel. DNA flow analysis demonstrated that cells began accumulating in G2/M within 6 hrs of exposure to paclitaxel; by 12 hrs over 50% of cells accumulated in G2/M at all concentrations tested. After 24 hrs of exposure to 10 nM paclitaxel, cells underwent non-uniform mitotic division resulting in multinucleated cells. Of cells treated with 30 nM to 1000 nM paclitaxel, 75% to 85% remained blocked in G2/M for up to 72 hrs. Although a large proportion of cells treated with higher concentrations of paclitaxel (10,000 nM) was blocked in G2/M, a significant proportion (10% to 40%) of these cells was also in G1. Cells exposed to lower concentrations of paclitaxel (10 nM to 1000 nM) in medium containing 0.135% (v/v) Cremophor EL also had a relatively large proportion in G1. Mitotic index studies demonstrated that the paclitaxel-induced G2/M block was initially a mitotic block and that cells remained in mitosis for up to 24 hrs. With additional time of exposure to paclitaxel, mitotic index and time-lapse studies indicated that cells attempted to complete mitosis; however, cytokinesis was inhibited and cells became multinucleated. Time-lapse photography revealed that paclitaxel markedly prolonged the time in mitosis from 0.5 hr to 15 hr. High levels of Cremophor EL (0.135% v/v) markedly reduced the number of cells in mitosis but did not alter the mitotic delay induced by paclitaxel. 3H-paclitaxel uptake studies revealed that high concentrations of Cremophor EL did reduce the rate of uptake of paclitaxel into cells but had little effect on total paclitaxel accumulation. These results confirm that paclitaxel has striking effects on the cell cycle and show that high concentrations of Cremophor EL are capable of inducing a cell cycle block distinct from the mitotic block seen with paclitaxel. These results also demonstrate that cells exposed to paclitaxel for longer than 24 hours attempt to complete mitosis but the process of cytokinesis is inhibited. Together with cytotoxicity data, these results indicate that entry into and exit out of mitosis are prerequisites for paclitaxel cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7904231     DOI: 10.1007/bf00685909

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

Review 1.  Taxol: an antimitotic agent with a new mechanism of action.

Authors:  J J Manfredi; S B Horwitz
Journal:  Pharmacol Ther       Date:  1984       Impact factor: 12.310

2.  Tubulin assembly sites and the organization of microtubule arrays in mammalian cells.

Authors:  S L Brenner; B R Brinkley
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1982

3.  Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs.

Authors:  D M Woodcock; S Jefferson; M E Linsenmeyer; P J Crowther; G M Chojnowski; B Williams; I Bertoncello
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

4.  Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.

Authors:  J E Liebmann; S M Hahn; J A Cook; C Lipschultz; J B Mitchell; D C Kaufman
Journal:  Cancer Res       Date:  1993-05-01       Impact factor: 12.701

5.  Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines.

Authors:  N M Lopes; E G Adams; T W Pitts; B K Bhuyan
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Phase I clinical and pharmacokinetic study of taxol.

Authors:  P H Wiernik; E L Schwartz; J J Strauman; J P Dutcher; R B Lipton; E Paietta
Journal:  Cancer Res       Date:  1987-05-01       Impact factor: 12.701

7.  Direct photoaffinity labeling of tubulin with taxol.

Authors:  S Rao; S B Horwitz; I Ringel
Journal:  J Natl Cancer Inst       Date:  1992-05-20       Impact factor: 13.506

Review 8.  Taxol: a novel investigational antimicrotubule agent.

Authors:  E K Rowinsky; L A Cazenave; R C Donehower
Journal:  J Natl Cancer Inst       Date:  1990-08-01       Impact factor: 13.506

9.  Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro.

Authors:  S M Hahn; J E Liebmann; J Cook; J Fisher; B Goldspiel; D Venzon; J B Mitchell; D Kaufman
Journal:  Cancer       Date:  1993-11-01       Impact factor: 6.860

10.  Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines.

Authors:  J E Liebmann; J A Cook; C Lipschultz; D Teague; J Fisher; J B Mitchell
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

View more
  17 in total

Review 1.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

2.  Cytotoxicity of fractionated paclitaxel (Taxol) administration in vitro.

Authors:  L Plasswilm; N Cordes; R Fietkau; R Sauer
Journal:  Strahlenther Onkol       Date:  1998-01       Impact factor: 3.621

3.  Differential effect of taxol in rat primary and metastatic prostate tumors: site-dependent pharmacodynamics.

Authors:  W C Yen; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

4.  Ultrastructural neuropathologic effects of Taxol on neurons of the freshwater snail Lymnaea stagnalis.

Authors:  H H Boer; C M Moorer-van Delft; L J Müller; B Kiburg; J B Vermorken; J J Heimans
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 5.  Progress in the development of alternative pharmaceutical formulations of taxanes.

Authors:  B Nuijen; M Bouma; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

Review 6.  [Combined radiochemotherapy of non-small-cell bronchial carcinoma with taxol].

Authors:  J Willner; M Flentje
Journal:  Strahlenther Onkol       Date:  1999-10       Impact factor: 3.621

Review 7.  Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Authors:  Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells.

Authors:  Cheng Jin; Ling Bai; Hong Wu; Wenjie Song; Guozhen Guo; Kefeng Dou
Journal:  Pharm Res       Date:  2009-04-21       Impact factor: 4.200

9.  Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway.

Authors:  C M Woods; J Zhu; P A McQueney; D Bollag; E Lazarides
Journal:  Mol Med       Date:  1995-07       Impact factor: 6.354

10.  Morelloflavone blocks injury-induced neointimal formation by inhibiting vascular smooth muscle cell migration.

Authors:  Decha Pinkaew; Sung Gook Cho; David Y Hui; John E Wiktorowicz; Nongporn Hutadilok-Towatana; Wilawan Mahabusarakam; Moltira Tonganunt; Lewis J Stafford; Amornrat Phongdara; Mingyao Liu; Ken Fujise
Journal:  Biochim Biophys Acta       Date:  2008-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.